1. Home
  2. BGLC vs MBIO Comparison

BGLC vs MBIO Comparison

Compare BGLC & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$2.14

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.75

Market Cap

5.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
MBIO
Founded
2017
2015
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2M
5.8M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
BGLC
MBIO
Price
$2.14
$0.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.1K
34.7K
Earning Date
04-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
45.78
98.99
EPS
N/A
N/A
Revenue
$7,424,911.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$0.53
52 Week High
$15.19
$7.00

Technical Indicators

Market Signals
Indicator
BGLC
MBIO
Relative Strength Index (RSI) 40.46 45.71
Support Level $2.14 $0.69
Resistance Level $2.73 $1.00
Average True Range (ATR) 0.06 0.04
MACD 0.00 0.01
Stochastic Oscillator 0.00 64.12

Price Performance

Historical Comparison
BGLC
MBIO

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: